Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leigongtengduogan + Yishen Juanbi Wan is a combination of two traditional Chinese medicine (TCM) products used primarily for the treatment of rheumatoid arthritis (RA). - **Leigongtengduogan** refers to Tripterygium glycosides, extracted from the herb Tripterygium wilfordii Hook F ("Thunder God Vine"), known for its immunosuppressive and anti-inflammatory properties. - **Yishen Juanbi Wan** is a classic TCM herbal compound formulation widely used in China to treat RA with kidney deficiency syndrome. It has demonstrated efficacy in reducing joint inflammation, inhibiting osteoclast differentiation, and protecting against bone destruction in both clinical and preclinical studies[1][2][4][5]. Mechanistically, it modulates immune responses by regulating T cell phenotypes (Th17/Treg balance), cytokine levels (IL-6, IL-17A, IL-10, TGF-beta1), and signaling pathways such as JAK2/STAT3[5]. This combination therapy is under investigation for its precise indications in RA management[2], aiming to leverage both the potent immunomodulatory effects of Tripterygium glycosides and the multi-targeted actions of Yishen Juanbi Wan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Leigongtengduogan + Yishen Juanbi Wan.